BofA raised the firm’s price target on Sarepta (SRPT) to $19 from $18 and keeps an Underperform rating on the shares after the company reported preliminary Q4 Elevidys revenues of $110M, below the firm’s and consensus estimates.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Balanced Risk Profile Amid Elevidys Uncertainty and PMO Regulatory Headwinds Supports Hold on Sarepta
- Sarepta Therapeutics: Resilient Fundamentals, Elevidys Recovery, and Pipeline Catalysts Underscore Attractive Buy‑Rated Upside
- Sarepta price action likely driven by softer Elevidys Q4 sales, says Jefferies
- Sarepta falls 10% to $21.37 after reporting preliminary Q4 revenue
- Sarepta reports preliminary Q4 net product revenue $369.9M